A new class of medicines for women
Our approach is driven by following science and innovation aimed at finding treatments for diseases that affect women. We are pioneering first-in-class, non-hormonal therapies with the potential to transform outcomes for billions of women worldwide.
CHM-001
Our lead investigational compound focuses on treating and slowing the disease progression of endometriosis in adult women while eliminating pain. CHM-001 is being investigated as a non-hormonal treatment for moderate-to-severe endometriosis-related pain, demonstrating disease-modifying effects. As a first-in-class new molecular entity, our pre-clinical data has demonstrated positive proof of concept and efficacy. CHM-001 has concluded its IND-enabling studies and plans to initiate its first-in-human Phase 1 clinical trials.
CHM-002
CHM-002 utilizes targeted nanoparticle technology to deliver combination drugs to treat pre-term labor. This compound has demonstrated efficacy in in-vitro, ex-vivo, and in-vivo studies. Our compound has been shown to reduce uterine contractions and prevent pre-term labor while preventing placental passage of drugs that cause fetal harm — a critical safety advancement for both mother and infant.
CHM-003
CHM-003 is our investigational compound targeting polycystic ovary syndrome (PCOS), one of the most common hormonal disorders affecting women of reproductive age. Our approach focuses on non-hormonal mechanisms to address the underlying pathophysiology of PCOS, including hormonal imbalance, irregular menstrual cycles, and metabolic dysfunction — offering a novel therapeutic option for the millions of women currently underserved by existing treatments.